{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:58:57Z","timestamp":1787979537697,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bulcan.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T11:51:25Z","timestamp":1681473085000},"page":"968-977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recommandations de la SFCE pour la prise en charge du lymphome de Hodgkin nodulaire \u00e0 pr\u00e9dominance lymphocytaire de l\u2019enfant et de l\u2019adolescent"],"prefix":"10.1016","volume":"110","author":[{"given":"Marie Emilie","family":"Dourthe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Haouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Ducou Le Pointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Jo Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah","family":"Boudjemaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Landman-Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.03.006_bib0170","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41375-022-01625-x","article-title":"The WHO classification of haematolymphoid tumours","volume":"36","author":"Cree","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.13979","article-title":"Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's children's cancer and leukaemia study group","volume":"173","author":"Shankar","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.13540","article-title":"Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - a review of clinical outcome based on the histological variants","volume":"171","author":"Shankar","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0190","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0195","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0200","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0205","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0210","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00043426-200205000-00010","article-title":"Lymphocyte-predominant Hodgkin disease in children","volume":"24","author":"Sandoval","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0220","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijrobp.2008.04.067","article-title":"Subsequent malignancies in children treated for hodgkin's disease: associations with gender and radiation dose","volume":"72","author":"Constine","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0230","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O\u2019Brien","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin's disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50\u00a0cases","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0245","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.006_bib0250","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/(SICI)1096-911X(199712)29:6<519::AID-MPO1>3.0.CO;2-N","article-title":"Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment\u2013the Pediatric Oncology Group experience","volume":"29","author":"Karayalcin","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0255","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on lymphoma project on lymphocyte-predominant Hodgkin's disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0260","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2141.2007.06736.x","article-title":"Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma\u2013a Children's Cancer and Leukaemia Group report","volume":"138","author":"Hall","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0265","first-page":"1700","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0270","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18169","article-title":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma\u00a0\u2013\u00a0All StAGEs: a\u00a0consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","author":"Shankar","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0275","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a lymphoma study association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0280","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7\u00a0to HD15\u00a0trials: a report from the german hodgkin study group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0285","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0290","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13879","article-title":"Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy","volume":"175","author":"Garciaz","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0295","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0300","doi-asserted-by":"crossref","DOI":"10.1097\/CCO.0000000000000774","article-title":"Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma","author":"Eichenauer","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0305","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0310","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0315","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0320","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0325","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma\u2013a report from the children's oncology group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.006_bib0165","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/bjh.16109","article-title":"Frontline management of nodular lymphocyte predominant Hodgkin lymphoma\u2013a retrospective UK multicentre study","volume":"186","author":"Wilson","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:33:51Z","timestamp":1726151631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0007455123001509"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations de la SFCE pour la prise en charge du lymphome de Hodgkin nodulaire \u00e0 pr\u00e9dominance lymphocytaire de l\u2019enfant et de l\u2019adolescent","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}